[go: up one dir, main page]

AR055420A1 - Derivados de pirimidina sustituidos - Google Patents

Derivados de pirimidina sustituidos

Info

Publication number
AR055420A1
AR055420A1 ARP060103924A ARP060103924A AR055420A1 AR 055420 A1 AR055420 A1 AR 055420A1 AR P060103924 A ARP060103924 A AR P060103924A AR P060103924 A ARP060103924 A AR P060103924A AR 055420 A1 AR055420 A1 AR 055420A1
Authority
AR
Argentina
Prior art keywords
alq
ilo
cycloalq
yloxy
halo
Prior art date
Application number
ARP060103924A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR055420A1 publication Critical patent/AR055420A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la formula general (1) donde: q es 0 o 1; R1 y R2 se seleccionan independientemente del grupo integrado por H y opcionalmente sustituido aril-alq(en/in)ilo C1-6, siempre que R1 y R2 no sean ambos H, o R1 y R2 junto con el N al cual ellos están unidos forman un anillo de 5 a 7 miembros que contiene opcionalmente otro heteroátomo; R3 y R4 se seleccionan independientemente de H, halogeno, ciano, amino, alq(en/in)ilo C1-6, cicloalq(en)ilo C3-8, halo- alq(en/in)ilo C1-6, halo-cicloalq(en)ilo C3-8 alq(en/in)iloxi C1-6, cicloalq(en)iloxi C3-8, cicloalq(en)il C3-8-alq(en/in)iloxi C1-6, halo-alq(en/in)iloxi C1-6, halo-cicloalq(en)iloxi C3-8 y halo-cicloalq(en)il C3-8-alq(en/in)iloxi C1-6, siempre que R3 y R4 no sean ambos H; R5 se selecciona del grupo integrado por alq(en/in)ilo C1-10, cicloalq(en)il C3-8-alq(en/in)ilo C1-6, opcionalmente sustituido aril-alq(en/in)ilo C1-6- y arilo opcionalmente sustituido; como base libre a sus sales.
ARP060103924A 2005-09-09 2006-09-08 Derivados de pirimidina sustituidos AR055420A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200501262 2005-09-09

Publications (1)

Publication Number Publication Date
AR055420A1 true AR055420A1 (es) 2007-08-22

Family

ID=37199174

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103924A AR055420A1 (es) 2005-09-09 2006-09-08 Derivados de pirimidina sustituidos

Country Status (15)

Country Link
EP (1) EP1937653A1 (es)
JP (1) JP2009507052A (es)
KR (1) KR20080043314A (es)
CN (1) CN101258133A (es)
AR (1) AR055420A1 (es)
AU (1) AU2006322461A1 (es)
BR (1) BRPI0615631A2 (es)
CA (1) CA2621854A1 (es)
EA (1) EA200800780A1 (es)
IL (1) IL189545A0 (es)
MX (1) MX2008002294A (es)
NO (1) NO20081713L (es)
UA (1) UA93387C2 (es)
WO (1) WO2007065449A1 (es)
ZA (1) ZA200802174B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97847C2 (ru) * 2007-08-01 2012-03-26 Х. Луннбек А/С Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010097379A1 (en) * 2009-02-24 2010-09-02 Neurosearch A/S Substituted pyrimidin derivatives and their medical use
JP5763758B2 (ja) * 2010-07-08 2015-08-12 ファイザー・インク Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド
WO2012052167A1 (en) * 2010-10-20 2012-04-26 Grünenthal GmbH Substituted 6-amino-nicotinamides as kcnq2/3 modulators
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
TWI664166B (zh) * 2014-10-24 2019-07-01 日商小野藥品工業股份有限公司 Ｋｃｎｑ２至５通道活化劑
ES3034153T3 (en) * 2019-08-02 2025-08-13 H Lundbeck As Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438231A1 (en) * 2001-02-20 2002-08-29 Gene G. Kinney 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use

Also Published As

Publication number Publication date
AU2006322461A1 (en) 2007-06-14
NO20081713L (no) 2008-06-04
CA2621854A1 (en) 2007-06-14
EP1937653A1 (en) 2008-07-02
WO2007065449A1 (en) 2007-06-14
CN101258133A (zh) 2008-09-03
KR20080043314A (ko) 2008-05-16
EA200800780A1 (ru) 2008-06-30
JP2009507052A (ja) 2009-02-19
IL189545A0 (en) 2008-06-05
ZA200802174B (en) 2009-10-28
UA93387C2 (ru) 2011-02-10
BRPI0615631A2 (pt) 2011-05-24
MX2008002294A (es) 2008-03-14

Similar Documents

Publication Publication Date Title
AR055144A1 (es) Inhibidor de secrecion acida
AR058776A1 (es) Compuesto de piridina condensado
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
ECSP11010912A (es) Compuestos de pirrol
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
ECSP055987A (es) Derivados de heteroarilcarbamoilbenceno
AR048778A1 (es) Derivados de pirrolidinilo como inhibidores de 11-beta hidroxiesteroide deshidrogenasa
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
AR048055A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
CO6270314A2 (es) Un derivado de y--amino acido biciclico que tiene una actividad como ligando (alfa)2(omega)
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR078606A1 (es) Derivados de piperidina para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR054369A1 (es) Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa
MX2019007684A (es) Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.
AR055420A1 (es) Derivados de pirimidina sustituidos
CO6481003A2 (es) Compuesto de benzazepina
DOP2011000296A (es) Compuesto de pirazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal